Launching Anxious Young Adults: A Specialized Cognitive-Behavorial Intervention for Transitional Aged Youth. Investigators: Anne Marie Albano, Lauren J Hoffman, John D Guerry
There has been growing clinical and research attention to the unique developmental stage of emerging adulthood. This stage is a time of significant change and growth for all individuals, as it includes identity exploration, emotional, behavioral, and financial independence from caregivers, and completion of educational or vocational requirements.
While evidence-based treatments exist for both child/adolescent anxiety disorders and adult anxiety disorders, no specialized assessment or treatment methods have been established for the unique period of emerging adulthood. The Launching Emerging Adults Program (LEAP) is a developmentally informed cognitive-behavioral treatment model that aims to simultaneously reduce anxiety symptoms and promote independence.
Publications:
Launching Anxious Young Adults: A specialized Cognitive Behavioral Intervention for Transitional Aged Youth. Hoffman LJ, Guerry JD, Albano AM. Launching Anxious Young Adults: A Specialized Cognitive-Behavioral Intervention for Transitional Aged Youth. Curr Psychiatry Rep. 2018 Mar 27;20(4):25. doi: 10.1007/s11920-018-0888-9. PMID: 29589127.
Examining what causes pathological anxiety in humans: DTI and resting state fMRI data from individuals with and without OCD. Investigators: Rachel Marsh PhD, X He, PhD
This research uses two specific types of neuroimaging – Diffusion Tensor Imaging (DTI) and resting state imaging – and compares results between non-OCD subjects, OCD subjects not on medication, and OCD patients on medication. Ultimately these studies may identify bio signatures of OCD that could become targets for new treatment development.
Publications:
Structural neural markers of response to cognitive behavioral therapy in pediatric obsessive-compulsive disorder. David Pagliaccio, Jiook Cha, Xiaofa He, Marilyn Cyr, Paula Yanes-Lukin, Pablo Goldberg, Martine Fontaine, Mora A. Rynn, Rachel Marsh. J Child Psychol Psychiatry. December 2020.
A test of a potential biomarker for exposure therapy outcome across development in anxious youth. Investigators: Michael Wheaton, PhD
Anxiety disorders typically begin in childhood or adolescence, have a high lifetime of prevalence, and when inadequately treated become chronic. Exposure therapy for anxiety and related disorders is an intervention with proven efficacy, yet for a significant percentage of treated individuals is not sufficient to achieve remission. The aim of this study is to expand our understanding of developmental differences in extinction learning and explore the potential impact on the efficacy of exposure therapy across development.
Publications:
The Role of Response Inhibition in Medicated and Unmedicated Obsessive-Compulsive Disorder Patients: Evidence From the Stop-Signal Task. Kalanthroff E, Teichert M, Wheaton MG, Kimeldorf MB, Linkovski O, Ahmari SE, Fyer AJ, Schneier FR, Anholt GE, Simpson HB. Depression and Anxiety. 2016.
Developing new treatments: Rapid Acting Therapeutics for OCD. Investigators: Moira Rynn, MD and Blair Simpson, MD, PhD
There is a compelling need for alternative pharmacological treatments in adolescents with OCD. In this pilot proposal, we will evaluate the feasibility, tolerability, and preliminary efficacy of ketamine as a rapid treatment for OCD symptoms in adolescents with OCD.
Investigating how and for whom our treatments work: Developing treatment-specific biomarkers for OCD. Investigators: Shannon Bennett, PhD, John Walkup, MD, Anne Marie Albano, PhD and Francis Lee, PhD, MD
The first-line psychotherapy for OCD is cognitive-behavioral therapy consisting of exposure and response prevention. However, some individuals are not helped by this treatment or experience a minimal reduction in symptoms. This study examines the effectiveness of exposure therapy across development in an effort to identify potential bio-behavioral markers of exposure therapy and outcomes in patients with childhood anxiety disorder. A treatment-specific biological marker (biomarker) could assist clinicians by identifying individuals for whom alternative treatment is necessary, personalizing medical care, and maximizing resource allocation.
A public health perspective on anxiety disorders in youth and young adulthood: phenomenology, course and treatment. Investigators: Cristiane Duarte PhD and Mark Olfson, MD
With the goal of generating novel findings of the highest public health significance for young adults with anxiety disorders, we are conducting secondary data analyses of population-based, longitudinal datasets. Specifically, we are focused on elucidating (a) the phenomenology and course of anxiety disorders in young adulthood, and (b) patterns of mental health treatment, given the substantial disparities in care observed among young adults.